LITHIUM: Wider Range of Effectiveness and Fewer Side Effects Than Assumed

> Robert M. Post, MD Editor: <u>www.bipolarnews.org</u> (click on Child Network)

Ashville, North Carolina PSYCHOPHARMACOLOGICAL UPDATE September 30, 2018

Potential Conflicts of Interest

Speaker for: (drug discussed)

Astra Zeneca......(quetiapine, Seroquel),

Sunovion..... (lurasidone, Latuda),

Validus...... (long acting CBZ, Equetro),

Takeda...... (vortioxetine, Trintellix), &

Pam Labs..... (I-methylfolate, Deplin)

Lithium: Present at the Origin of the Universe

- Lithium appeared 20 minutes after the Big Bang, supranova → fusion of hydrogen
- Quarks contributed to baryons, yielding Lithium (Li), Helium (He), Beryllium (Be)
- Salt (Na+Cl-) emerged millions of years after the Big Bang
- Without lithium, animals develop abnormally

 \mathbf{O}

 Lithium should be considered an essential element daily dose of 1000mg/day for 70kg human

Investigators in the Bipolar Collaborative Network (BCN):

4 sites in United	States	3 sites in Europe	
UCLA 1. Los Angeles	3.Cincinnati	HC Rumke Group 1. Utrecht	
Lori AltshulerMark Frye	Paul KeckSue McElroy	Willem NolenRalph Kupka	
UTSW 2. Dallas	NIMH 4. Bethesda	2. Freiburg	
• Trisha Suppes	 Gabriele Leverich Robert Post 	 Jörg Walden 3.^{Munich} 	
		• Heinz Grunze	

In BCN, 956 patients were studied and treated longitudinally

More Familial Psychiatric Illness and Psychosocial Adversity in the U.S. Compared to Europe

In U.S. THERE WAS MORE:

I. <u>GENETIC/FAMILIAL Risk:</u>

- A. Grandparental Illness
- **B.** Parental Illness
- C. Sibling & Spouse
- **D.** Offspring Illness

III. Adverse COURSE OF ILLNESS:


- A. Earlier Age of Illness
- B. More Episodes (> 20 and R.C.)
- C. More Anxiety Disorder
- D. More Substance Abuse
- E. More Medical Comorbidities

II. ENVIRONMENTAL Adversity

- A. Childhood Abuse
- **B.** Loss of Social Support
- C. Financial/Employment
- **D. Health and Care Access**

IV. Treatment NONRESPONDERS

- A. Fewer Well on entry
- B. Fewer long-term Responders
 (for ≥ 6 months) to naturalistic
 treatment



Avoiding Treatment Resistance


- I. Attempt primary prophylaxis in those at high risk
- II. Treat Prodromal syndromes
- III. Treat continuously (preventively) after 1st mania
- IV. Prevent illness recurrence and progression
- V. Treat anxiety and substance abuse comorbidities
- VI. Use intensive multi-modal treatment for Rx refractory patients
- VII. More medications with different mechanisms of action will be required

Lithium is Under-Utilized in the Treatment of Bipolar Disorder

 This is particularly true in the US, were more anticonvulsant mood stabilizers, such as divalproex (valproate), and atypical antipsychotics are used, and, regrettably, antidepressants are the most widely prescribed drug class for newly diagnosed patients with bipolar disorder.

Initial Treatment of Bipolar Disorders in the United States 2002–2003: Not on Target

Antidepressant monotherapy: twice as common as mood stabilizers



N = 7,760 patients with bipolar disorder; 69% BP I, 16% BP II, 14% BP NOS Baldessarini R, et al. *Psychiatr Serv.* 2007;58(1):85-91.

Assets of Lithium: Beyond its Antimanic Effects

Lithium:

- Prevents unipolar and bipolar depressions
- Increases hippocampal and cortical volume
- Reduces dementia diagnosis in old age
- (150mg/day slows progression over 1 year of MCI)
- Has anti-suicide effects

(at clinical doses and at miniscule doses in water supply)

- Increases and normalizes length of telomeres
- Reduces incidence of some neurological disorders; cancers

Lithium Increases Every Kind of Stem Cell (Gallichio, 2011)

- Bone marrow (pluripotent hematopoietic stem cells)
- Somatic induced pluripotent stem cells (iPSCs) (lithium normalizes the increased excitability of iPSCs from bipolar patients)

Mesenchymal derived stem cells (MSCs)

Brain Derived Neural Stem Cells (NSCs)

Lithium Reduces Lesion Size in Animal Models of:

1. Stroke/ischemia (even AFTER the ligation of the middle cerebral artery)

- 1. Alzheimer's disease
- 2. Parkinson's disease
- 3. Tauopathies
- 4. Huntington's disease
- 5. AIDs encephalopathy

Lithium Reduces Rehospitalization in Unipolar Dep.

123,712 hosp. in Finland; mean follow up 7.7 years (1996-2012) in national registry. (J. TIIHONEN ET AL 2018)

LITHIUM LOWERED RISK OF RE-HOSPITALIZATION (HR 0.47)

Antidepressants didn't lower risk of re-hospitalization(HR 1.10)

Antipsychotics did not lower risk of rehospitalization (HR 1.16) Except clozapine which did lower risk (HR 0.65)

LITHIUM RISK LOWEST WHEN USED WITHOUT AN AD (HR 0.33)

LITHIUM USED WITH A CONCOMITANT AD (HR 0.65)

Lithium side effects have been over-estimated, and most can be avoided or dealt with

- LITHIUM CAN CAUSE CREATININE CREEP:
- Loss of renal function does not start for 15-30 years
- Is not associated with end-stage renal damage
- End-stage renal damage is more common with anticonvulsants
- Avoiding episodes of lithium toxicity may prevent damage

- LITHIUM CAUSES THYROID DYSFUNCTION
- This can readily be treated with thyroid replacement

• LOWER DOSES OF LITHIUM WILL AVOID MOST OTHER EFFECTS

Lithium: Once a day (od) is superior to b.i.d and t.i.d (Plenge, 1982)

<u>O.D. vs. 2-3x/day:</u>

Increased convience/compliance

- Decreased urinary volume
- Decreased number of sclerotic glomeruli
- Decreased fibrosis and atrophic granules

New Message: Treat Intensively and Continuously After a First Mania

AFTER A MANIC HOSPITALIZATION:

 Randomization to 2 years of expert specialty clinic* leads to fewer relapses than with treatment as usual over the next 6 years! (*includes illness education, psychotherapy, drug Rx, mood monitoring)

(Kessing et al 2013)

2. Cognition declines --

And recovers over the next year only if there are no further episodes (Yatham et al 2017

and Demmo et al 2017)

3. Randomization to

1 year of <u>lithium</u> is superior to <u>quetiapine</u> on all measures: (ie. mania, depression, functioning, cognition, brain imaging)


(Berk et al 2017)

After a First Mania, One Year of Lithium Beats One Year of Quetiapine for:

- 1) Less mania
- 2) Better functioning
- 3) Better cognition
- 4) Better quality of life
- 5) Less depression
- 6) Less white matter reduction
- 7) More neuroprotective markers on MRS
- 8) More normalization of connectivity

Randomized Specialty Bipolar Clinic vs Treatment As Usual (TAU)


- Specialty clinic for 2 years vs TAU showed markedly decreased relapses and enhanced compliance.
- Differences persisted and grew stronger over 6 years



Kessing, LV et al. BJP. 2013;2012:212-219.


Early Expert Intervention and Patient Education Changes the Long Term Course of Illness

Two Thirds of Bipolar Disorder in the U.S. Begins in Childhood or Adolescence (< age 19)



HEAT MAP: Higher I.) FAMILY ILLNESS BURDEN and II.) ADVERSITY IN CHILDHOOD

HAVE ADDITIVE EFFECTS ON EARLIER AGE OF ONSET OF BIPOLAR DISORDER



Average Age of Onset (years)

II.) Total Childhood Abuse

Mean age of onset is 26 years with no vulnerability factors; Onset is in childhood (<13 years) with high levels of both abuse and family illness burden Early Onset is associated with Longer Delays to First Treatment.

 Both Early Onset and Treatment Delay are independent risk factors for poor outcome in adulthood.

--- Treatment delay is a remedial risk factor---

US Patients with Bipolar Disorder Are More III Than The EUROPEANS

	US (N=676)	EUROPE (N=292)
ANXIETY DISORDER	46.6%***	28.1%
ALCOHOL ABUSE	33.1%***	14.7%
SUBSTANCE ABUSE	38.3%***	17.8%
RAPID CYCLING	74.1%***	41.5%
> 20 EPISODES	59.0%***	23.3%
Hospitalizations	Fewer**	More
PROSPECTIVE NON-RESPONDERS	51.7%***	31.1%

GREATER ILLNESS BURDEN IN OFFSPRING OF BIPOLAR PROBANDS FROM THE US vs EUROPE

Any Illness	36.3%	13.3%
Other	24.9%	5.1%
SUBSTANCE Abuse	12.0%	2.1%
• ETOH ABUSE	7.2%	1.4%
Suicide attempt	6.0%	2.2%
• Bipolar	17.8%	3.8%
UP Depression	26.5%	8.9%
Offsprings Dx :	US	Europe

EVEN GREATER ILLNESS BURDEN IN 74.2% of OFFSPRING OF A BIPOLAR PARENT IN A 7 YEAR PROSPECTIVE FOLLOW-UP STUDY in the US (AXELSON ET AL, 2015)


Of	fsprings Dx : Depression	Axelson (BP) 32.0%	US (BP) 26.5%	Europe (BP) 8.9%	US (Controls) 4.9%
•	Bipolar	22.5%	17.8%	3.8%	2.0%
•	Suicide att'pt		6.0%	2.2%	
•	Alcohol Abuse		7.2%	1.4%	
•	Substance Ab	19.9%	12.0%	2.1%	10.1%
	Other (Anxiet	y) 39.9%	24.9%	5.1%	21.8%
•	Any:	74.2%	36.3%	13.3%	46.8%

Remarkably, 46.8% THE OFFSPRING Of the COMMUNITY CONTROLS (Axelson et al, 2015) (ie, US PARENTS WITHOUT BIPOLAR DISORER) Have a Major Psychiatric Diagnosis on Follow up

How will we address the epidemic of childhood onset psychiatric disorders in the US?

- 1. Ignore the data; find alternative explanations
- 2. Note the data, but play "ostrich"
- 3. Call for "more studies"OR
- Begin to actively address the problem with treatment studies that help generate new information and point to new directions for intervention.
 - Build on what works and discard what doesn't.
 - Combine science and practice.
 - A practical clinical trials network

Intervention Needed at Earlier Stages of Bipolar Illness Evolution



Preventive Strategies for those at Very High Risk as a Function of the Risks of the Treatment Intervention

Prevention Type I, II, III:

<u>I Primary</u> Good Diet Exercise Omega-3-Fatty Acids Mindfulness

NO RISK

II Secondary
Psychotherapy
N-acetylcysteine
Omega-3Fatty Acids
Minocycline
E-M power

LOW RISK Rx

III <u>Tertiary</u> Lithium (Li) Li + VPA $AA \pm CBZ$

HIGHER RISK Rx

We Need to Be Alert to Childhood Onsets of Not Only Bipolar disorder, but also anxiety, depression, and externalizing disorders

PEDIATRICIANS Need to Ask About Children's Psychological as well as Medical Health (Shonkoff and Gardner, 2012)


ADULT PSYCHIATRISTS Need to Ask about the Health of the Children of their Patients with Bipolar Disorder and Depression (Post, et al 2017)

PARENTS Can take a proactive stance to assist clinicians in their child's evaluation. They can sign up for the Child Network at **www.bipolarnews**. org

DISCRIMINATORS* OF PREPUBERTAL ONSET


BIPOLAR DISORDER AND ADHD

^periods of Sadness




 1) BRIEF (illustrated above)
 Or 2) EXTENDED MOOD ELEVATION
 3) DECREASED NEED FOR SLEEP
 4) Greater Degrees of

- Irritability
- 5) Poorer Frustration Tolerance



- 3) Change in Appetite
- 4) Physical Complaints
- 5) Inappropriate SEXUAL Behavior




5) Decreased Self-Esteem

• Based on Linear Mixed Model; Dysfunction For Each Symptom:

LACK OF TREATMENT AND APPROPRIATE TREATMENT IN THE US

- 2.2% of US children aged 13-18 have a bipolar spectrum diagnosis, yet Most Children Are Not in Treatment;
 Only 22% Are in Treatment (Merikangus et al, 2011)
- In Carefully Diagnosed Children with BPD; 37% of the Children Treated in the Community Never Received Any Consensus Recommended Treatment (Li, MS, AA) During 8 Years of Follow Up.
- Those who received LITHIUM showed the most time in REMISSION. (Geller et al 2010)

Prevent the Accumulation of Stress and Episode-Related Vulnerability in Recurrent Affective Illness



Each Type of Sensitization and Cross-Sensitization Can Be Lessened or Prevented with Appropriate Treatment Interventions

Stress Sensitization

- PSYCHOEDUCATION
- Social support
- Psychotherapy
- Stress Coping
- Family Rx

Substance Abuse Sensitization

Episode Sensitization

• PSYCHOEDUCATION

Primary Prevention •Rx of Risk factors

 Tertiary Prevention
 •Rx of Abused substances

- PSYCHOEDUCATION
- Early Initiation of Prophylaxis
- Combination treatment (Rx)
- Complex Rx of comorbidities
 - Adjunctive Psycho Rx & Medications

Also Better Treatment of a Parent's Depression or Bipolar Disorder Results in Fewer Psychiatric Illnesses in the Offspring


(Weissman et al 2006)

In Refractory Bipolar Disorder:


- Be carefully therapeutically aggressive and innovative.
- Test what really works in an individual patient*.
- Your patient's Response/Nonresponse/SE's trumps all guidelines, FDA approval, and academic pronouncements.

*Personal Calendar and Child Network weekly ratings available at: "bipolarnews.org"

A Life Chart Picture is Worth 100,000 Words



Personal calendar available: www. bipolarnews.org



More Prior Episodes or Rapid Cycling Predicts Poor Response to Almost All Treatments

- I. NATURALISTIC TREATMENT
- II. MOOD STABILIZERS (M.S.)
 - Lithium
 - Carbamazepine
 - Lamotrigine
 - Valproate (Accelerating course), Calabrese; Post 2012(t)
- III. ATYPICAL ANTIPSYCHOTICS (A.A.)
 - Olanzepine
 - Any A.A.
- IV. ANTIDEPRESSANT AUGMENTATION OF A M.S.
 - Venlafaxine
 - Any AD
- V. BENZODIAZEPINES

Post 2004; Nolan 2005

 > 14 studies (except Baldessarini & Tondo 2000) McKeon 1992; Otusa 1993; Denicoff 1997 Frye et al 2000; Obrocea 2002
 urse), Calabrese; Post 2012(t)

> Ketter 2006; Berk 2011 Post 2010

Post 2006

Ghaemi 2010; Post 2012(t)

Post 2012(t)

VI. COGNITIVE BEHAVIORAL THERAPY (CBT) Scott, 2006

For Bipolar Disorder:

"An Ounce of Prevention, Is Worth a Pound of Cure".....or

"A Few Hundred mgs of Prevention Is Worth 20 Kilograms of Acute Treatment"


Correlates of Response to Mood Stabilizers

D				LAMOTRIGINE
Drug:	LITHIUM	<u>CARBAMAZEPINE</u>	VALPROATE	
Subtype:	BPI	BPII	BPI or II	BPI & II
Comorbid				
 Substance 	None	Alcohol &	Alcohol	
Abuse:		Substance Use		
● Anx. Dx	No Anxiety	Anxiety (PTSD)	Anxiety (PTSD)	Anxiety (PTSD)
Manic Affect	Euphoric >	Dysphoric =	Dysphoric =	N.A.
	Dysphoric	Eurphoric	Eurphoric	
Mood Incongruent	None	Yes, SA	±	±
Delusions				
Discrete	Episodic;	±	±	Cyclic, Continuous
Episodes	Well Intervals			
Fewer Prior				
Episodes or \downarrow	Yes	Yes	(±Yes)	Yes
Rapid Cycling			(
Family Hx	Bipolar Illness,	Negative for		Anxiety Disorders!
Positive	Li Response	Bipolar Illness	?	& Substance Abuse
Single Nucleotide				
Polymorphism	5HT-T _{ss}			
Others	Antisuicide, Medical	Paroxysmal Pain	Migraine	For Prevention Not For acute Rx;
	Morbidity	Syndromes		slow titration required (serious rash)

Approved Agents for Bipolar Depression: AAs Work, (ADs Do Not)

Olanzapine-Fluoxetine¹

Quetiapine²



**P*<0.001; [‡]*P*≤0.001; [†]*P*≤0.01; [§]*P*<0.05. 1. Tohen M et al. *Arch Gen Psychiatry*. 2003;60:1079-1088.

Calabrese JR et al. Am J Psychiatry. 2005;162:1351-1360.
 Loebel A et al. Am J Psychiatry. 2014;171:160-168

Lurasidone³

Combinations Are More Effective Than Monotherapy in Bipolar Disorder Prophylaxis

Lithium plus carbamazepine (CBZ)

Lithium plus valproate (VPA)

Denicoff et al

Calabrese et al. (Adults) Findling et al. (Children) Geddes et al. 2010, BALANCE

VPA plus lamotrigine (LTG) (better than VPA Alone)

Atypical Antipsychotics as Adjuncts to Lithium or Valproate (better than Li or VPA Alone) Quetiapine plus lamotrigine Bowden et al.

Most AAs are FDA-Approved as Adjuncts to M.S.

Geddes et al

Rationales for Complex Combination Therapy

- Necessary in Other Chronic Medical Conditions (AIDs, TB, CHF, Cancer, Epilepsy)
- Differential Targeting of Multiple Systems, Symptoms, and Comorbidities
- Failure of Mono or Dual Therapy
- Avoidance of Side Effects
- Wish to Treat to Full Remission and Prevent Loss of Efficacy

One Schema for Treatment of Rapid Cyclers

Start with Combination Treatment:

I. Lithium + VPA;	II. Lithium + CBZ/OXC; or	III. Lithium + LTG
(Dysphoric mania)	(Schizoaffective, BPII)	(Depressions
(-)	Substance abuse)	nrodominatos)

Plus Adjuncts For:

- A. Agitation/Insomnia: CLONAZEPAM, LORAZEPAM, OR GABAPENTIN
- B. <u>Psychosis:</u> ATYPICAL ANTIPSYCHOTICS
- C. <u>Persistent Cycling:</u> THIRD MOOD STABILIZER
- D. <u>Weight Loss</u>: TOPIRAMATE, ZONISAMIDE, BUPROPION + NALTREXONE
- E. <u>Alcoholism:</u> TOPIRAMATE, ZONISAMIDE, GABAPENTIN, NAC
- F. <u>Ultradian Cycling</u>: NIMODIPINE (dihydropyridine Ca++ blocker)
- G. <u>Atypical Depression:</u> BUPROPION, MAOI
- H. <u>Cocaine:</u> TOPIRAMATE, MODAFINIL, NAC


Convergent Mechanisms of Cross Sensitization to Stressors, Episodes, and Cocaine Suggest that a Single Therapy Could Improve All Three

N-acetylcysteine (NAC) as a possible example NAC Reduces: **Addictions to: Cocaine, Gambling, Alcohol, Marijuana, Nicotine. **Trichotillomania, OCD, PTSD **Depression and Anxiety in Bipolar Disorder

Hyperactive Cued Glutamate Release from Cortical Neurons onto N. Accumbens Neurons May Be the Basis of Multiple Addictions and Habits

N-acetylcysteine (NAC) Increases (grows) Glial Glutamate Transporters, Dampens Conditioned Glutamate Release, and Is Effective in Many Habits & Addictions

Decreasing Glutamate-Induced Neuronal Hyperactivity that Drives Habits and Addictions



N-acetylcysteine (NAC)*: Efficacy in Repetitive Habit Disorders

١.	DRUG ADDICTION	III. TRICHOTILLOMANIA	VI. <u>BP DEPRESSION</u>
	Cocaine		
	Alcohol	IV. OCD (Augumentation	VII. <u>UP DEPRESSION?</u>
	Marijuana	<u>of SSRI)</u>	
	Nicotine**		VIII. <u>Negative Sx</u>
		V. <u>Stereotypy & Irritability</u>	<u>SCHIZOPHRENIA</u>
11.	<u>GAMBLING</u>	in AUTISM***	
	ADDICTION.		<u>IX. PTSD</u>

 * Typical dosing versus placebo: NAC 500mg B.i.d. for 1 week, then 2 caps (1000 mg) BID thereafter
 ** 1,500mg BID
 *** max daily dose = 2,700mg

Drugs Targeting Multiple Comorbidities

<u>NAC:</u> Cocaine, (N –acetyl- Alcohol, cysteine) Gambling, Smoking, Marijuana, OCD (+SSRI)

<u>VPA:</u> (Valproate)

Migraine, Anxiety Alcohol **Topiramate:**

Alcohol Cocaine Bulimia Anger Attacks Migraine

<u>Zonisamide:</u> Al Βι

Alcohol Bulimia

<u>Gabapentin:</u> Anxiety Social Phobia Alcohol Pain

Modafinil: Cocaine ADHD Narcolepsy Results of 10 Randomized Trials of Family Focused Therapy (FFT) for Patients with Bipolar Disorder (Miklowitz et al, 2017)

- Total 1,140 patients (adjunctive to medications)
 - Five trials with bipolar adults
 - Two with bipolar adolescents
 - Three with youth at high risk
 - Comparisons included brief psychoeducation or equally intensive individual therapy
- Patients in FFT had greater benefits over 1-2 years in:
 - Depression stabilization (Cohen's d = 0.49 to 0.56)
 - Recurrence risk (RR= 0.79)
 - Psychosocial functioning/Quality of Life (d = .96)

Attempting to Stop Illness Progression

WHAT PROGRESSES?

- 1. Episodes come faster and more automatically
- 2. Stressors accumulate and sensitize
- Substance abuse increases and sensitizes
 1,2,3; have long term epigenetic mechanisms
 1,2,3; each shortens telomeres
- 4. Cognitive dysfunction as function of number of episodes;4 lifetime depressions doubles risk of dementia in old age
- 5. Medical comorbidities
- 6. Loss of brain volume (prefrontal cortex)
- 7. Premature loss of years of life expectancy

A Bottom Line Is: We Should Use Lithium More Often

• And we should use lithium earlier:

(Earlier initiation of lithium is more effective than starting after many episodes; in 9 of 10 studies) and, most recently Kessing et al 2014.

Starting lithium after the first manic episode is associated with a better outcome than starting quetiapine (Berk et al 2017), and it may have neuroprotective and cognitive protective effects.

Chronic treatment with lithium:

- Prevents manias and depressions
- Reduces suicide rate
- Reduces medical comorbidities
- Increases telomere length
- Increases longevity
- Prevents cognitive deterioration
- Decreases incidence of dementia in old age

Tell Patients about Lithium' Wide Range of Assets

Clinically in Bipolar Disorder

Decreases:

- Depression; Mania
- Suicide
- Progression to dementia
- UP Depression (AD potentiation)

Increases:

- Telomere length
- Physical health
- Hippocampal & cortex volume
- Low dose:
- 150mg protects MCI
- Li in water decreases suicides

Basic in laboratory animals

Decreases:

- Cell death factors BAX and P53
- Apoptosis
- Inflammation
- Lesion size in models of: HC, Alzheimer's, stroke AIDs, trauma

Increases:

- Neuroprotective Factors BDNF and BCL-2
- Neuronal stem cells

Conclusions

- Bipolar disorder is a progressive, relatively treatment resistant illness: prophylactic Rx after a first mania
- Lithium should be used more often because of its multiple benefits
- Treatment may require complex combination therapy: "More medications, FEWER effects"
- Treatment resistance, cognitive dysfunction, and medical comorbidities increase as a function of number of prior episodes
- Patients need a new mantra:
 - "Prevent episodes, protect the brain and body"

CONCLUSIONS:

Treat Aggressively from the FIRST EPISODE Onward

The goal is achieving and maintaining **REMISSION**

Complex COMBINATION treatment may be required

Re-think about using LITHIUM more often

Treatment resistance and cognitive dysfunction increase with increasing numbers of episodes

The new mantra is: "PREVENT EPISODES, PROTECT THE BRAIN AND BODY"